4.6 Article

Occupational exposures and 20-year incidence of COPD: the European Community Respiratory Health Survey

期刊

THORAX
卷 73, 期 11, 页码 1008-1015

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/thoraxjnl-2017-211158

关键词

copd epidemiology; occupational lung disease

资金

  1. Australia: Asthma Foundation of Victoria
  2. Australia: Allenand Hanbury's
  3. Belgium: Belgian Science Policy Office
  4. Belgium: National Fundfor Scientific Research
  5. Estonia: Estonian Science Foundation [1088]
  6. France: Ministere de la Sante
  7. France: Glaxo France
  8. France: InsitutPneumologique d'Aquitaine
  9. France: Contrat de Plan Etat-Region Languedoc-Rousillon
  10. France: CNMATS
  11. France: CNMRT [90MR/10, 91AF/6]
  12. France: Ministredelegue de la sante, France
  13. France: RNSP, France
  14. France: GSF
  15. Germany: Bundesminister fur Forschung und Technologie
  16. Italy: Ministero dell'Universita edella Ricerca Scientifica e Tecnologica
  17. Italy: CNR
  18. Italy: Regione Veneto grant [381/05.93]
  19. Norway: Norwegian Research Council [101422/310]
  20. Spain: Fondo de Investigacion Sanitaria [91/0016-060-05/E, 92/0319, 93/0393, PS09/02457, PS09/0071609/01511, PS09/02185 PS09/03190]
  21. Spain: Hospital General deAlbacete
  22. Spain: Hospital General Juan Ramon Jimenez
  23. Spain: DireccionRegional de Salud Publica (Consejeria de Sanidad del Principado deAsturias)
  24. Spain: CIRIT [1997 SGR 00079]
  25. Spain: Servicio Andaluz de Salud
  26. Sweden: The Swedish Medical Research Council
  27. Sweden: Swedish Heart LungFoundation
  28. Sweden: Swedish Association against Asthma and Allergy
  29. Switzerland: Swiss national Science Foundation [4026-28099]
  30. UK: National Asthma Campaign
  31. UK: British Lung Foundation
  32. UK: Department ofHealth
  33. UK: South Thames Regional Health Authority
  34. Australia: National Health AMP
  35. Medical ResearchCouncil
  36. Antwerp City: Research FoundationFlanders (FWO) [G.0.410.08.N.10]
  37. Estonia: Estonian Ministry of Education [Tartu-SF0180060s09]
  38. France: Ministere de la Sante. Programme Hospitalier de RechercheClinique (PHRC) national 2010
  39. Bordeaux: INSERM UniversiteBordeaux segalen [U897]
  40. Grenoble: Comite Scientifique AGIRadom 2011
  41. Paris:Agence Nationale de la Sante
  42. Paris: Region Ile de France
  43. Erfurt: German ResearchFoundation [HE 3294/10-1]
  44. Hamburg: German Research Foundation [MA711/6-1, NO 262/7-1]
  45. Iceland: Reykjavik
  46. Iceland: Landspitali UniversityHospital Research Fund
  47. Iceland: University of Iceland Research Fund
  48. Iceland: ResMedFoundation, California, USA
  49. Iceland: Orkuveita Reykjavikur (Geothermalplant)
  50. Iceland: Vegageroin (The Icelandic Road Administration (ICERA)
  51. Italy: Italian Ministry ofHealth, Chiesi Farmaceutici SpA
  52. Italy: Cariverona foundation, Education Ministry (MIUR)
  53. Norway: NorwegianResearch council [214123]
  54. Norway: Western Norway Regional HealthAuthorities [911631]
  55. Norway: Bergen Medical Research Foundation
  56. Spain: Fondo de Investigacion Sanitaria
  57. Spain: SociedadEspanola de Neumologia y Cirurgia Toracica [SEPAR 1001/2010]
  58. Sweden: Swedish Heart and LungFoundation
  59. Sweden: Swedish Asthma and Allergy Association
  60. Sweden: SwedishAssociation against Lung and Heart Disease
  61. Fondo de InvestigacionSanitaria [PS09/02457]
  62. Barcelona: Fondo de Investigacion Sanitaria [FIS PS09/00716]
  63. Galdakao: Fondo de Investigacion Sanitaria [FIS09/01511]
  64. Huelva: Fondo de Investigacion Sanitaria [FIS PS09/02185]
  65. Servicio Andaluz de Salud Oviedo: Fondo de InvestigacionSanitaria [FIS PS09/03190]
  66. Sweden: TheSwedish Heart and Lung Foundation
  67. Sweden: Swedish Asthma and AllergyAssociation
  68. Sweden: Swedish Association against Lung and Heart Disease
  69. Goteborg : Swedish Council for Working life and Social Research
  70. Vasterbotten Country Council ALF grant
  71. Switzerland: SwissNational Science Foundation [33CSCO-134276/1, 33CSCO-108796, 3247BO-104283, 3247BO-104288, 3247BO-104284, 3247-065896, 3100-059302, 3200-052720, 3200-042532, 4026-028099]
  72. Sweden: Federal office for forest, environment and landscape
  73. Sweden: FederalOffice of Public Health
  74. Sweden: Federal Office of Roads and Transport
  75. canton's government of Aargan
  76. canton's government of Basel-Stadt
  77. canton's government of Geneva
  78. canton's government of Luzern
  79. canton's government of Ticino
  80. canton's government of Valais
  81. canton's government of Zurich
  82. Swiss Lung League
  83. Freiwillige AkademischeGesellschaft
  84. UBS Wealth Foundation
  85. Talecris Biotherapeutics GmbH
  86. Abbott Diagnostics
  87. European Commission [018996]
  88. WellcomeTrust [WT 084703MA]
  89. UK: Medical Research Council [92091]
  90. National Institute for Health Researchthrough the Primary Care Research Network
  91. ECRHS III through the Medical Research Council [92091]
  92. European Union's Horizon 2020 research andinnovation programme [633212]
  93. Medical Research Council [G0901214] Funding Source: researchfish
  94. MRC [G0901214] Funding Source: UKRI

向作者/读者索取更多资源

Background Occupational exposures have been associated with an increased risk of COPD. However, few studies have related objectively assessed occupational exposures to prospectively assessed incidence of COPD, using postbronchodilator lung function tests. Our objective was to examine the effect of occupational exposures on COPD incidence in the European Community Respiratory Health Survey. Methods General population samples aged 20-44 were randomly selected in 1991-1993 and followed up 20 years later (2010-2012). Spirometry was performed at baseline and at follow-up, with incident COPD defined using a lower limit of normal criterion for postbronchodilator FEV1/FVC. Only participants without COPD and without current asthma at baseline were included. Coded job histories during follow-up were linked to a Job-Exposure Matrix, generating occupational exposure estimates to 12 categories of agents. Their association with COPD incidence was examined in log-binomial models fitted in a Bayesian framework. Findings 3343 participants fulfilled the inclusion criteria; 89 of them had COPD at follow-up (1.4 cases/1000 person-years). Participants exposed to biological dust had a higher incidence of COPD compared with those unexposed (relative risk (RR) 1.6, 95% CI 1.1 to 2.3), as did those exposed to gases and fumes (RR 1.5, 95% CI 1.0 to 2.2) and pesticides (RR 2.2, 95% CI 1.1 to 3.8). The combined population attributable fraction for these exposures was 21.0%. Interpretation These results substantially strengthen the evidence base for occupational exposures as an important risk factor for COPD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据